Persistent adverse effects of finasteride in younger men include erectile dysfunction, low libido, lack of orgasms, depression, and decreased alcohol consumption. One study has found lower levels of several neurosteroids in this population. Out of the various persistent side effects, erectile dysfunction and decreased alcohol consumption have been the most studied in animal models. Further research is needed on who is susceptible to the persistent adverse side effects of finasteride and on the underlying mechanisms of the medication. Irwig MS. Persistent sexual and non-sexual adverse effects of finasteride in younger men. Sex Med Rev 2014;2:24–35.
Recent postmarketing reports and a US Food and Drug Administration analysis have documented uncommon persistent sexual and nonsexual side-effects in a subset of younger men who have taken finasteride 1 mg for androgenic alopecia. While the mechanisms of the sexual side-effects in humans is incompletely understood, one study found lower cerebrospinal fluid concentrations of dihydrotestosterone, progesterone, dihydroprogesterone and allopregnanolone, and higher levels of testosterone, 5α-androstane-3α,17β-diol and pregnenolone. Another study found up-regulation of the androgen receptor in the human foreskin with a mean of 5 years after finasteride discontinuation.
MDA level was significantly higher in the cortex, the hippocampus and caudate nucleus in TAA vs . control group 24 h after the administration of the last dose of TAA (p<). In contrast, TAA did not induce a significant change in MDA level in the thalamus ( ± nmol/mg prot.) when compared with control ( ± nmol/mg prot., p>). While FIN alone reduced MDA level in the cortex ( ± nmol/mg prot., p<), the hippocampus ( ± nmol/mg prot., p<) and the thalamus ( ± nmol/mg prot., p<), and increased its level in caudate nucleus ( ± nmol/mg prot., p<), in FIN+TAA group MDA level was significantly higher in hippocampus ( ± nmol/mg prot., p<), caudate nucleus ( ± nmol/mg prot., p<) and thalamus when compared with control ( ± and ± nmol/mg prot. in hippocampus and caudate nucleus respectively, Fig 2A ).